VIRTTU

<< Back to companies search

 

Virttu has pioneered the development of oncolytic viruses for treating cancer. Although viruses naturally kill the cells they infect, weakened viruses have been used in medicine for centuries as vaccinations against the infectious diseases they cause. Scientists at Virttu have reprogrammed this ability in a common human virus so that it targets and kills only cancer cells (oncolysis), leaving normal cells unharmed. Additionally, the presence of the tumour-specific viral infection works as a vaccination triggering the patient’s own immune system to mount an anti-cancer response a treatment known as oncolytic immunotherapy.

 

 

Location

BioCity Glasgow

 

Company Type

Lab and office

 

Sector

Antibodies, Vaccines